AI
Tuesday, March 17, 2026 10:01:36 AM
Gabagool,
Thanks for reposting your free medical expertise & analysis again 😶
Fact ✅️: In addition to independently peer-reviewed papers in JNS, Nature Comms, & JAMA Oncology, NWBO’s pipeline also has the validation of rigorously peer-reviewed competitive grants awarded by the 🇺🇸U.S. NIH-NCI & the 🇺🇸U.S. DoD. Those government agencies have supported & are currently supporting the clinical development of DCVax®-L & the polarized aDC1 platform.
✅ DCVax®-L
✅ DCVax®-Direct
✅ Polarized aDC1 Platform
Dr. Sheheryar Kabraji is the principal of this
PII combo trial funded by a peer-reviewed grant from the 🇺🇸U.S. DoD.
Regarding the DCVax®-L PIII trial, everyone appreciates the free opinions of “Gabagool Research,” but we’ll leave the analyses & conclusions to the independent peer reviewers & the respected physicians who led the landmark trial.
Dr. Ashkan
Dr. Liau
To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.
☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.
☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.
☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primary endpoint.
The field of immuno-oncology is advancing rapidly, with next-gen dendritic cell tech emerging as a key component in targeted, personalized, & less toxic NEXT-GEN COMBO therapies!
COMBO trials are a very recent development. Checkpoint inhibitors have only been commercially available since 2014, & DC combos with PD1 blockade technology have only recently reached PII.
“They called me Gabagool Research”
AI Fact-Checking
Thanks for reposting your free medical expertise & analysis again 😶
Fact ✅️: In addition to independently peer-reviewed papers in JNS, Nature Comms, & JAMA Oncology, NWBO’s pipeline also has the validation of rigorously peer-reviewed competitive grants awarded by the 🇺🇸U.S. NIH-NCI & the 🇺🇸U.S. DoD. Those government agencies have supported & are currently supporting the clinical development of DCVax®-L & the polarized aDC1 platform.
✅ DCVax®-L
✅ DCVax®-Direct
✅ Polarized aDC1 Platform
Dr. Sheheryar Kabraji is the principal of this
PII combo trial funded by a peer-reviewed grant from the 🇺🇸U.S. DoD.
Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt
— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025
Regarding the DCVax®-L PIII trial, everyone appreciates the free opinions of “Gabagool Research,” but we’ll leave the analyses & conclusions to the independent peer reviewers & the respected physicians who led the landmark trial.
Dr. Ashkan
Dr. Liau
To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.
☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.
☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.
☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primary endpoint.
The field of immuno-oncology is advancing rapidly, with next-gen dendritic cell tech emerging as a key component in targeted, personalized, & less toxic NEXT-GEN COMBO therapies!
COMBO trials are a very recent development. Checkpoint inhibitors have only been commercially available since 2014, & DC combos with PD1 blockade technology have only recently reached PII.
“They called me Gabagool Research”
AI Fact-Checking
Bullish
I am a long NWBO shareholder. Views expressed are my own, and I have no affiliation with the company.
